Home / Companies / Cartesian Therapeutics, Inc. / 12 Jun 2026
Cartesian Therapeutics, Inc.: meeting of 12 Jun 2026
Votes reported on Form N-PX, item by item
132 Form N-PX filers reported votes at the Cartesian Therapeutics, Inc. meeting of 12 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 51.3% of reported votes for; 38 filers withheld from or voted against at least one nominee.
273 vote records from 50 filers. 25 of the 50 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
191 vote records from 132 filers. 10 of the 125 filers that marked the item either way voted against management. 7 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
91 vote records from 50 filers. 0 of the 50 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| State Street and SPDR | For | For | For |
| Invesco | No report | Against * | No report |
| Equitable | Abstain or withhold * | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | Abstain or withhold * | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | Abstain or withhold * | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | No report | For | No report |
| Northern Trust and FlexShares | For | For | For |
| T. Rowe Price | Abstain or withhold * | For | For |
| Lincoln Financial | For | For | For |
| Voya | For | For | For |
| Russell Investments | No report | For | No report |
| Nationwide | Abstain or withhold * | For | For |
| Victory Capital | Abstain or withhold * | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | Abstain or withhold * | For | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| AllianceBernstein | No report | For | No report |
| DWS | Abstain or withhold * | For | For |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Cartesian Therapeutics, Inc. meeting?
132 Form N-PX filers reported votes at the meeting of 12 Jun 2026. On say-on-pay, 10 of 125 voted against management (8.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Cartesian Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Cartesian Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Cartesian Therapeutics, Inc. with a meeting date within three days of 12 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.